## **BioVision**

08/14

<b>Product:</b>	NSC 405020 3,4-Dichloro- <i>N</i> -(1-methylbutyl)benzamide	RELATED PRODUCTS:   Batimastat (Cat. No. 1704-1)   Doxycycline hyclate (Cat. No. 2209-100, 500)   GM6001 (Cat. No. 1799-1)   Marimastat (Cat. No. 1790-1, 5)   MMP-3 Inhibitor, NNGH (Cat. No. 2569-5, 25)   MMP-3 Activity Fluorometric Assay Kit (Cat. No. K783-100)   MMP-3 Inhibitor Screening Kit (Fluorometric) (Cat. No. K793-100)   MMP-9 Antibody (Cat. No. 3529-100)   MMP-9 Antibody (Cat. No. 3565-100)   MMP-9, human recombinant (Cat. No. 7789-10, 50, 1000)   MMP-9 Inhibitor (Cat. No. 1981-500)   TAPI-0 (Cat. No. 2067-1)   TAPI-1 (Cat. No. 2068-1)
CATALOG #:	2682-5, 25	
	5 mg, 25 mg	
STRUCTURE:	CI CH3	
MOLECULAR FORMULA:	$C_{12}H_{15}CI_2NO$	EZSolution™ TAPI-1 (Cat. No. 2540-1)
MOLECULAR WEIGHT:	260.16	TAPI-2 (Cat. No. 2069-1)
CAS NUMBER:	7497-07-6	
APPEARANCE:	Off-white solid	
SOLUBILITY:	DMSO (>25 mg/ml) or EtOH (>25 mg/ml)	
PURITY:	≥98% by HPLC	
STORAGE:	Store at -20 °C. Protect from air and light	
DESCRIPTION:	NSC-405020 is a membrane type-I matrix metalloproteinase (MT1-MMP) inhibitor that specifically targets the hemopexin (PEX) domain rather than the catalytic domain of MT1-MMP (IC <sub>50</sub> >100 µmol/L). It does not inhibit the catalytic activity of MT1-MMP or MMP-2. NSC-405020 directly interacts with and binds to PEX in a vicinity of Met-328, Arg-330, Asp-376, Met-22 and Ser-470 of the druggable pocket in the full-length MT1-MMP structure, which affects the conformation and flexibility of blades I to IV of the $\beta$ -propeller resulting in the decrease of the PEX-dependent homodimerization of cellular MT1-MMP.	
REFERENCES:	Remacle, A.G., et al. (2012). Cancer Res. 72, 2339-2349.	
HANDLING:	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.	FOR RESEARCH USE ONLY! Not to be used on humans.